Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: Biologics

The Future of Pediatric Rheumatology Grounded in Evolution of Childhood Arthritis and Rheumatology Research Alliance

Yukiko Kimura, MD, & Laura E. Schanberg, MD  |  

Pediatric rheumatology was formally recognized as a specialty in 1991 by the American Board of Pediatrics. Prior to this time, children with rheumatic diseases were treated by a hodgepodge of providers. In addition to providers who had training as pediatric rheumatologists, general pediatricians, adult rheumatologists, allergist-immunologists, orthopedists, pediatric infectious disease specialists and others treated children…

Infection Greater Worry Than Flare: Collaborative Guideline Offers Guidance to Prevent Joint Replacement Complications & Failure

  |  

WASHINGTON, D.C.—Total joint arthroplasty is one of the most common surgical procedures performed on adults with end-stage arthritis. One recent estimate showed that 2.5 million individuals in the U.S. are living with a total hip replacement and 4.7 million are living with knee replacements. For their patients with inflammatory arthritis, rheumatologists and orthopedic surgeons must…

The 2016 ACR Award Winners Discuss Their Contributions to Rheumatology Research, Education, Patient Care

  |  

At the 2016 ACR/ARHP Annual Meeting in Washington, D.C., in November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. In the November 2016 issue, we reported on the ARHP’s awards. This month, we speak with the ACR winners. Presidential Gold…

U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight

Brendan Pierson  |  

WASHINGTON (Reuters)—The U.S. Supreme Court on Monday declined to hear a case over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval before bringing them to the market. The justices opted not to take up Apotex Inc.’s appeal of a July federal appeals court ruling that could…

Health Policy Resolutions from the AMA House of Delegates 2016 Interim Meeting

  |  

This year’s interim meeting of the American Medical Association (AMA) House of Delegates (HOD) took place Nov. 12–15, just days after the national election that, in 2017, will usher in a GOP-led Congress and presidential administration. “It was a highly interesting meeting,” says Gary Bryant, MD, FACP, associate professor of medicine and rheumatology at the University…

FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline

  |  

The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…

Transfer of Certolizumab in Breast Milk Not a Concern

Reuters Staff  |  

NEW YORK (Reuters Health)—There is minimal to no transfer of the tumor necrosis factor (TNF) inhibitor certolizumab (Cimzia) from plasma to breast milk, according to a new study. “These findings are reassuring” and imply that continuing certolizumab treatment is compatible with breastfeeding, Dr. Megan Clowse of Duke University School of Medicine in Durham, North Carolina,…